Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 21, 2016

View Archived Issues

Veliparib does not demonstrate clinically significant QTc prolongation in phase I trial

Atrin Pharmaceuticals wins NCI contract to develop ATR inhibitors

SOBI-003 granted European orphan drug status

New Canadian-African trial to study Ebola vaccine VSV-EBOV in subjects with HIV

Redx nominates new drug development candidate from reversible BTK inhibitor program

Glucox Biotech discloses Nox4 inhibitors

CFDA accepts CStone Pharmaceuticals' IND for anti-PD-L1 monoclonal antibody

Novel DNA vaccines against Zika virus infection enter phase I study

Ionis Pharmaceuticals presents promising clinical data for IONIS-APO(a)Rx and IONIS-APO(a)-LRx

NBE Therapeutics and SOTIO to develop next-generation ADCs

FDA grants rare pediatric disease designation to Kuros Biosciences' KUR-112

Institute of Materia Medica of Beijing patents deoxytylophorinine derivatives

Merck & Co. describes novel azacarbazole derivatives

Bristol-Myers Squibb identifies new AP2-associated protein kinase 1 inhibitors

Araxes Pharma presents novel KRAS Gly12Cys mutant inhibitors

Enanta Pharmaceuticals divulges anti-hepatitis B virus agents

Twice daily DA-5204 equal to thrice daily Stillen for treating gastritis

Advaxis begins part B of KEYNOTE-046 trial

ProMetic Life Sciences reports results from phase II study of PBI-4050

EMA awards priority medicine designation to CymaBay Therapeutics' MBX-8025

NIH grant to support study of Capricor Therapeutics' CAP-2003

HedgePath Pharmaceuticals provides interim data from phase IIb study of SUBA-Itraconazole

Debiopharm enters clinical collaboration with Merck KGaA and Pfizer

Karolinska Development company Dilaforette to change name to Modus Therapeutics

Positive topline results from FORWARD-5 pivotal phase III study of ALKS-5461 in patients with MDD

FIT phase III trials and open-label extension study show consistent benefit of fostamatinib

High rate of response seen with dabrafenib in pediatric low-grade gliomas

Johnson & Johnson offers overview of third quarter 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...